Background: Immune thrombocytopenic purpura (ITP) is characterized by reduced platelet count secondary to immunemediated destruction, this results in an increased bleeding risk. Autoantibodies binding to platelets tag them for premature destruction in the spleen. For this reason, splenectomy is often performed as treatment of chronic forms of disease that are resistant to pharmacological therapy. Methods: We studied 30 patients with ITP and compared them with age-matched controls. results: We show that B cells of patients with chronic ITP are intrinsically hyperreactive, producing more than normal IgG in vivo and plasma cells in vitro. In normal individuals after splenectomy, a significant depletion of memory B cells is observed, associated with loss of reactivity to CpG oligodeoxynucleotide and consequent inability to form antibody-producing cells. In Enzyme-Linked ImmunoSpot Methods, we compared three splenectomized ITP patients relapsing after surgery, 30 healthy controls, and 37 individuals splenectomized for trauma, spherocytosis, thalassemia, nonhematological tumor, and other diseases. conclusions: We confirmed that B cells of ITP patients remain hyperreactive in vitro and form high numbers of antibody-producing cells after splenectomy. Thus, chronic ITP may be associated with intrinsic B-cell hyperfunction, leading to the production of antibodies with multiple specificities including that against platelets.
i mmune thrombocytopenic purpura (ITP) is an acquired immune-mediated disorder characterized by isolated thrombocytopenia, defined as a peripheral blood platelet count below 100 × 10 9 /l, in the absence of any obvious initiating and/or underlying cause of thrombocytopenia. ITP is generally considered to be a benign disorder in children, with an incidence of 2 to 5 per 100,000 children younger than 15 y (1). ITP is classified by duration as newly diagnosed (less than 3 mo), persistent (3-12-mo duration), and chronic (>12-mo duration) (2) .
ITP in children is usually short lived with at least two-thirds of affected patients recovering spontaneously within 6 mo (3).
Signs and symptoms vary widely. Many patients have either no symptoms or minimal bruising, whereas few others experience serious bleeding, which may include gastrointestinal or intracranial hemorrhage (4) . The bleeding risk correlates to some extent, but not completely, with the severity of thrombocytopenia (5) . Additional factors (e.g., age, lifestyle, uremia) affect the risk and should be evaluated before the appropriate management is determined (6, 7) . Treatment is rarely indicated in patients with platelet counts above 50 × 10 9 /l in the absence of the following conditions: bleeding, trauma, and surgery (8) . Only 3% of children with ITP have clinically significant symptoms, such as severe epistaxis or gastrointestinal bleeding. Severe bleeding is more likely to occur in children with platelet counts less than 50 × 10 9 /l. The incidence of intracranial hemorrhage in children with ITP is ~0.1-0.5% (9) .
If treatment is necessary for acute ITP, the first-line/initial options are intravenous immunoglobulin (10) and corticosteroids (11) . Treatment options for children with persistent/ chronic ITP include intravenous immunoglobulin and corticosteroids as first-line treatment, followed by rituximab, cyclosporine, azatioprine, and other immunosuppressive drugs. A number of studies with thrombopoietin-receptor agonists, which increase platelet production, have shown encouraging results in adults, but finalized studies are not yet available to support the use of these agents in children. Splenectomy is an effective treatment for pediatric ITP, although it carries the risk of sepsis that persists for life (12) .
ITP is characterized by the production of autoantibodies that bind to platelets targeting them for phagocytosis by macrophages in the spleen (13) and liver (14) . Consequently, the life span of platelets is shortened, and bone marrow production cannot compensate destruction. Other mechanisms, including T-cell-mediated cytotoxicity (15) and impaired platelet production, have also been demonstrated to cause ITP (16, 17) .
The still incompletely defined pathophysiology of the disease contributes to explain why there is no "best treatment" for all patients (16, 18) .
B cells have been at the center of attention for many years, and rituximab, a humanized antibody binding to the B-cell Articles CD20 antigen, has been used with the intention of removing autoreactive B-cell clones. Several studies, both in adults and in children, have shown a significant initial response in 40% of the cases and a long-lasting (5 y) response in 20-25% (19) . For patients relapsing after rituximab therapy, splenectomy is often the only choice to overcome disease. Recently, a very interesting study has investigated the reasons of rituximab failure in patients who had to be splenectomized after antibody treatment (20) . The results demonstrated that rituximab depletes CD20 + B cells not only in peripheral blood but also in the spleen, where only 0.2-1% of B cells survived most of which were memory B cells and plasma cells. These antibody-producing cells were shown to have the genetic signature of long-lived plasma cells and are not sensitive to anti-CD20 depletion. Despite rituximab removed CD20+ B cells but splenic long-lived plasma cells persisted so the clinical success was not achieved. Noteworthy that splenectomy after rituximab cured the disease in only 7 out of 10 patients suggesting that, in some cases, autoreactive B cells may also be generated elsewhere (21) .
We have shown previously that, in patients with systemic lupus erythematosus, B cells able to produce autoantibodies are included in the memory B-cell pool, thus disease persistence or relapse may be caused by the periodical reactivation of these autoreactive memory B cells (22) .
We studied the memory B-cell compartment and function in a cohort of pediatric ITP patients in order to identify a possible defect associated with the disease that could justify the pharmacological targeting of this cell type.
RESULTS

B-cell Phenotype in Pediatric ITP Patients
Peripheral blood mononuclear cell (PBMC) from pediatric ITP patients (described in Table 1 ) and healthy controls were stained with antibodies to CD19, CD24, CD27, CD38, IgM, and IgD and analyzed by flow cytometry in order to characterize B-cell subsets. The population of memory B cells can be identified as CD19 + CD27 + (Figure 1a , left) and includes IgM memory B cells, expressing IgM and IgD, and switched memory B cells, carrying Ig of other isotypes (Figure 1a, right) . The percentages of total memory, switched and IgM memory B cells, were calculated in the B cell gate. As frequency and absolute number of memory B cells change with age, we compared ITP children with healthy controls of the same age. Four age-groups were created including a total of 131 healthy controls. There was no significant difference among the frequency of total memory, IgM, and switched memory B cells of patients and controls in any of the four age-groups analyzed (Figure 1b) . Similarly, absolute numbers of memory B cells in patients were not different from the absolute numbers in the age-matched controls (Figure 1c) .
The Response to Toll-Like Receptor 9 Stimulation in the ITP Patients
Toll-like receptor 9 (TLR9) is engaged by hypomethylated DNA (cytosine-phosphate-guanine (CpG)); we have previously demonstrated that in vitro TLR9 triggers memory B-cell proliferation and differentiation into antibody-producing cells (23, 24) . Consequently, CpG stimulation can be used to measure the function and specificity of memory B cells. We have shown that in patients with systemic lupus erythematosus, autoantibodies can be detected in the supernatant of stimulated PBMC (22) .
We asked the question whether PBMC from ITP patients respond to CpG and produce antiplatelet antibodies. In order to answer this question, PBMC from 30 healthy control and 30 ITP patients (7 newly diagnosed, 3 persistent, and 20 chronic) (Figure 2a ). Low responders were mostly newly diagnosed and persistent ITP cases, whereas the majority of chronic ITP patients were in the responder group (Figure 2b) . Next, we analyzed culture supernatants to assess immunoglobulin secretion. We found that, as expected, Ig were not spontaneously secreted (not shown), but after CpG stimulation, the production of antibodies of all isotypes was induced. In the supernatants of PBMC from ITP patients, the concentration of IgM and IgA was lower than in healthy controls, whereas IgG were increased in the chronic ITP group (Figure 2c ). As patients with newly diagnosed and persistent ITP showed an impaired proliferative response to CpG, a low antibody production was an expected result. Antiplatelet antibodies could not be measured in the supernatants probably due to insufficient sensitivity of our method of detection, which is normally used to measure antibodies in the serum where their concentration is at least 3 logs higher (mg/ml instead of µg/ml).
Immunoglobulins in the supernatants derived from antibody-producing cells differentiated in vitro upon CpG stimulation. We compared the frequency of total B cells and plasma cells in the CpG cultures of controls (that all respond to CpG) with the frequency of the same populations in the group of ITP patients able to react to CpG. This group, as already reported, was mostly composed of chronic ITP patients. We found that total B cells were lower than that in the controls (P < 0.0001), but plasma cells of both IgM and switched isotype were Articles significantly increased (Figure 2d) . Thus, chronic ITP patients show a reduced proliferative response to CpG (resulting in a low frequency of total B cells) associated with a significantly increased ability to terminally differentiate into plasma cells.
Plasma Levels of Ig in ITP Patients
In order to evaluate whether the higher ability to secrete antibodies in vitro could be demonstrated also in vivo, we compared the concentration of immunoglobulins in the plasma of ITP patients and 30 healthy controls. For patients treated with intravenous immunoglobulin, plasma was collected at least 1 mo after the last administration. We found that IgG levels were significantly increased compared with the controls (Figure 3a) . In order to evaluate whether all antibodies were equally increased in the serum independent of their specificity, we measured antitetanus toxoid and antipneumococcal polysaccharide IgG (anti-PnPS). We found that these specificities were in the normal range (Figure 3b,c) .
Splenectomy Does Not Influence Antibody Production in ITP Patients
Splenectomy is a largely employed treatment of chronic ITP of childhood when all other therapies, including rituximab, have failed. We analyzed PBMCs from three patients diagnosed Articles Giordano et al.
with ITP in childhood and splenectomized several years before our analysis. We have shown in previous studies that splenectomy is associated with an extreme reduction of the B-cell memory pool (25, 26) . In contrast with these observations, in our splenectomized ITP patients, the frequency of memory B cells was in the normal range with a prevalence of switched memory B cells (Figure 4a) . By Enzyme-Linked ImmunoSpot Methods (ELISPOT), we measured the number of memory B cells able to generate antibody-producing cells in vitro after CpG stimulation. We first compared the number of spots generated by memory B cells of control adults with those produced by memory B cells of 37 age-matched splenectomized individuals without primitive disease affecting the immune system. As expected, the number of spots was significantly reduced in the splenectomized controls. In contrast, each of the splenectomized ITP patients generated more spots of each isotype in comparison not only to splenectomized adults but also to normal adult controls (Figure 4b) . By ELISPOT, it is also possible to test the specificity of the antibody produced. Memory B cells against a vaccine antigen, such as tetanus, are mostly of IgG isotype. These were significantly reduced in splenectomized adults and also lower in the ITP patients when compared with controls. In contrast, IgM memory B cells producing antitetanus antibodies were lower in the splenectomized controls but not in ITP patients (Figure 5a,b) .
Different results were obtained for pneumococcal polysaccharides. Pneumococcus is a common pathogen often colonizing the upper respiratory ways. Its polysaccharides represent the prototype T-independent antigen. We have shown that the response to this type of antigens is primarily due to IgM memory B cells (23) a population that is usually depleted after splenectomy (25) . The response also generates IgG and IgA. Splenectomized individuals have a significant reduction of antipneumococcus IgA and IgG spots (Figure 5c ) and also of IgM spots (Figure 5d) (26) . In splenectomized ITP patients, IgG and IgA were not reduced and IgM spots were increased as compared with controls and splenectomized adults. Thus, IgM memory B cells do not diminish after splenectomy in ITP patients with severe disease (Figure 5d) .
DISCUSSION
Antibodies are molecules that, thanks to their ability to specifically recognize pathogens, cure infections and prevent relapses.
Autoimmune diseases are often characterized by the presence of antibodies that are not directed against foreign antigens and bind instead the one's own constituents. Antiplatelet antibodies cause ITP. The reasons leading to the production of autoantibodies remain mostly unknown. Animal models and human studies have identified several check points during B-cell development in the bone marrow and antigen-induced differentiation in the periphery, where induction of tolerance occurs purging the B-cell repertoire of dangerous specificities.
Although ITP has often a benign clinical course, in some cases, the reduced number of platelets remains a lifelong problem that cannot be solved by the available therapies. The various duration of disease and severity of clinical symptoms suggest that platelet destruction might be the common feature of ITP forms with different etiopathogenesis.
We found that B-cell function was altered in ITP, especially in the chronic forms. 
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Although B-cell numbers were comparable between patients and age-matched controls and B-cell populations were normally distributed (Figure 1) , we found that ITP memory B cells showed an increased ability of generating plasma cells and secreted higher amounts of antibodies especially of IgG isotype in vitro (Figure 2) .
The increased capacity of producing antibodies in vitro was correlated with a significantly higher level of IgG in the serum (Figure 3a) .
In normal individuals, serum antibodies of IgG isotype are produced by long-lived plasma cells generated by previous immune responses and residing in the bone marrow (27) (28) (29) (30) . Articles Giordano et al.
For example, antitetanus and antipneumococcal polysaccharide IgG antibodies in the serum are produced by this mechanism. The concentration of specific IgG was not increased in ITP patients (Figure 3b,c) , suggesting that protective immunity is not altered in ITP. Splenectomy is performed in ITP patients with the aim of sparing from destruction platelets tagged by autoantibodies. We have shown that the removal of the spleen causes depletion of both IgM and switched memory B cells (Figure 4a, right) (25, 26, 31) . The reduction of IgM memory B cells remains a permanent characteristic of splenectomized individuals, whereas switched memory B cells are slowly regenerated over time (31) (32) (33) . We analyzed three ITP patients years after splenectomy. We found that in contrast to our observation in normal individuals, both IgM and switched memory B cells were present in these three patients (Figure 4a, right) . Memory B cells were able to respond to CpG and generated a high number of antibody-producing cells detectable in ELISPOT. The number of spots was higher in splenectomized ITP than that in controls with or without spleen (Figure 4b) . We tested the specificity of memory B cells against two prototype antigens, tetanus toxin, which generates a T-dependent response, and pneumococcal polysaccharides, which are T-independent antigens ( Figure 5) . The frequency of B cells producing IgG and IgA against tetanus was reduced, whereas IgM antibody-producing cells were increased as compared with controls. For pneumococcus, IgG and IgA were not diminished, and IgM were higher than that in normal or splenectomized controls.
The question of how antibodies against platelets are produced is not solved. The idea of a mistake in tolerance induction during a normal germinal center response may explain the forms of disease that are cured by steroids and/or rituximab. Our results suggest that chronic ITP, relapsing after rituximab and splenectomy, might be associated with a constitutive B-cell defect leading to the T-and probably antigenindependent production of antibodies with different specificity including that against platelets. Our data are in agreement with the recent observation that proliferative lymphoid nodules containing B cells and follicular dendritic cells, but distinct from germinal centers, are found in the spleen of ITP patients. T cells were reduced, and BCL-6 was not expressed in proliferative lymphoid nodules containing B cells, suggesting that 
